4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Second round statewide sentinel-based population survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India, during January-February 2021

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , *
      IJID Regions
      The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
      SARS-CoV-2, sentinel survey, clinical sensitivity, serosurvey, Karnataka

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Demonstrate the feasibility of using the existing sentinel surveillance infrastructure to conduct the second round of the serial cross-sectional sentinel-based population survey. Assess active infection, seroprevalence, and their evolution in the general population across Karnataka. Identify local variations for locally appropriate actions. Additionally, assess the clinical sensitivity of the testing kit used on account of variability of antibody levels in the population.

          Methods

          The cross-sectional study of 41,228 participants across 290 healthcare facilities in all 30 districts of Karnataka was done among three groups of participants (low, moderate, and high-risk). The geographical spread was sufficient to capture local variations. Consenting participants were subjected to real-time reverse transcription-polymerase chain reaction (RT-PCR) testing, and antibody (IgG) testing. Clinical sensitivity was assessed by conducting a longitudinal study among participants identified as COVID-19 positive in the first survey round.

          Results

          Overall weighted adjusted seroprevalence of IgG was 15.6% (95% CI: 14.9–16.3), crude IgG prevalence was 15.0% and crude active infection was 0.5%. Statewide infection fatality rate (IFR) was estimated as 0.11%, and COVID-19 burden estimated between 26.1 to 37.7% (at 90% confidence). Further, Cases-to-infections ratio (CIR) varied 3-35 across units and IFR varied 0.04–0.50% across units. Clinical sensitivity of the IgG ELISA test kit was estimated as ≥38.9%.

          Conclusion

          We demonstrated the feasibility and simplicity of sentinel-based population survey in measuring variations in subnational and local data, useful for locally appropriate actions in different locations. The sentinel-based population survey thus helped identify districts that needed better testing, reporting, and clinical management. The state was far from attaining natural immunity during the survey and hence must step up vaccination coverage and enforce public health measures to prevent the spread of COVD-19.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Antibody responses to SARS-CoV-2 in patients with COVID-19

          We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

            Abstract Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. Methods A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. Results Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). Conclusions The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

              During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2 1–5 . Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titers: less than 1:50 in 33% and below 1:1000 in 79%, while only 1% showed titers >1:5000. Antibody sequencing revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
                Bookmark

                Author and article information

                Journal
                IJID Regions
                The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
                2772-7076
                2772-7076
                30 October 2021
                December 2021
                30 October 2021
                : 1
                : 107-116
                Affiliations
                [1 ]Department of Health and Family Welfare Services Aarogya Soudha, 1st cross, Magadi road, Bengaluru, Karnataka 560023
                [2 ]Department of Health and Family Welfare Services Aarogya Soudha, 1st cross, Magadi road, Bengaluru, Karnataka 560023
                [3 ]Indian Institute of Science, CV Raman Rd, Bengaluru, Karnataka 560012
                [4 ]Indian Statistical Institute – Bengaluru Centre, 8th Mile, Mysore Rd, RVCE Post, Bengaluru, Karnataka 560059
                [5 ]Department of Health and Family Welfare Services Aarogya Soudha, 1st cross, Magadi road, Bengaluru, Karnataka 560023
                [6 ]Department of Health and Family Welfare Services, Aarogya Soudha, 1st cross, Magadi road, Bengaluru, Karnataka 560023
                [7 ]UNICEF, Karnataka, Aarogya Soudha, 1st cross, Magadi road, Bengaluru, Karnataka 560023
                [8 ]Department of Health and Family Welfare Services, Government of Karnataka, Vikasa Soudha, Bengaluru, Karnataka 560008
                [9 ]Department of Health and Family Welfare Services, Aarogya Soudha, 1st cross, Magadi road, Bengaluru, Karnataka 560023
                [10 ]Indian Institute of Public Health- Bengaluru, Public Health Foundation of India, Magadi Rd 1st cross, next to leprosy hospital, SIHFW premises, Bengaluru, Karnataka 560023
                [11 ]Indian Institute of Public Health- Bengaluru, Public Health Foundation of India, Magadi Rd 1st cross, next to leprosy hospital, SIHFW premises, Bengaluru, Karnataka 560023
                [12 ]Indian Institute of Public Health- Bengaluru, Public Health Foundation of India, Magadi Rd 1st cross, next to leprosy hospital, SIHFW premises, Bengaluru, Karnataka 560023
                [13 ]Indian Institute of Public Health- Bengaluru, Public Health Foundation of India, Magadi Rd 1st cross, next to leprosy hospital, SIHFW premises, Bengaluru, Karnataka 560023
                [14 ]National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka 560029
                [15 ]VRDL, Bangalore Medical College and Research Institute, Fort, K.R. Road, Bengaluru, 560002
                [16 ]ICMR-National Institute of Virology, Bengaluru Unit, Someshwaranagar, 1st Main, Dharmaram College Post, Bengaluru 560029
                [17 ]Vijayanagar Institute of Medical Sciences, Ballari Karnataka 583104
                [18 ]VRDL, Bangalore Medical College and Research Institute, Fort, K.R. Road, Bengaluru, 560002
                [19 ]VRDL Hassan Institute of Medical Sciences, Sri Chamarajendra Hospital Campus, Krishnaraja Pura, Hassan, Karnataka 573201
                [20 ]VRDL, Shimoga Institute of Medical Sciences, Sagar Road, Shimoga, Karnataka, 577201
                [21 ]VRDL Mysore Medical College and Research Institute, Irwin Road, Mysuru Karnataka, 570001
                [22 ]Gulbarga Institute of Medical Sciences, Veeresh Nagar, Sedam Road Kalaburagi, Karnataka, 585105
                [23 ]Karnataka Institute of Medical Sciences, PB Rd, Vidya Nagar, Hubli, Karnataka, 580022
                [24 ]Institute of Nephro Urology, Victoria Hospital Campus, Bengaluru, 560002
                [25 ]Chairman, Technical Advisory Committee on COVID-19, Department of Health and Family Welfare Services Aarogya Soudha, 1st cross, Magadi road, Bengaluru, Karnataka 560023
                [26 ]National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka, 560029
                [27 ]Indian Institute of Public Health – Bengaluru, Public Health Foundation of India, Magadi Rd 1st cross, next to leprosy hospital, SIHFW premises, Bengaluru, Karnataka, 560023
                Author notes
                [* ]Corresponding author: Dr. Giridhara R. Babu, Indian Institute of Public Health – Bengaluru, Public Health Foundation of India, Magadi Rd 1st cross, Next to Leprosy Hospital, SIHFW premises, Bengaluru, Karnataka 560023, Telephone number: +919845036197
                Article
                S2772-7076(21)00021-7
                10.1016/j.ijregi.2021.10.008
                8620812
                35721769
                8c3363f5-ba93-422e-b932-5351af1eea1e
                © 2021 The Authors

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 21 August 2021
                : 20 October 2021
                : 22 October 2021
                Categories
                Article

                sars-cov-2,sentinel survey,clinical sensitivity,serosurvey,karnataka

                Comments

                Comment on this article